Related Experiment Video

Updated: Aug 9, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

Sodium channel block by a potent, new antiarrhythmic agent, transcainide, in guinea pig ventricular myocytes

P B Bennett, R Stroobandt, H Kesteloot

    Journal of Cardiovascular Pharmacology
    |June 1, 1987
    PubMed

    Insights

    Transcainide, a novel lidocaine analog, effectively suppresses cardiac arrhythmias by potently blocking sodium channels. Its unique, time- and voltage-independent action requires cautious clinical application due to limited reversibility.

    Area of Science:

    • Cardiovascular Pharmacology
    • Cardiac Electrophysiology
    • Molecular Pharmacology

    Background:

    • Cardiac arrhythmias pose a significant clinical challenge, necessitating novel therapeutic agents.
    • Lidocaine analogs are established antiarrhythmic drugs targeting cardiac sodium channels.
    • Initial clinical trials suggest transcainide efficacy in suppressing arrhythmias.

    Purpose of the Study:

    • To investigate the electrophysiological effects of transcainide on cardiac sodium channels.
    • To determine the concentration-dependence, use-dependence, and voltage-dependence of transcainide's sodium channel block.
    • To characterize the reversibility of transcainide-induced sodium channel block.

    Main Methods:

    • Whole-cell patch-clamp technique applied to guinea pig ventricular myocytes.
    • Concentration-response relationship determined for transcainide's effect on sodium current.
    • Assessment of use-dependence using 10-Hz pulse trains.
    • Evaluation of voltage-dependence by hyperpolarizing cells to -160 mV.
    • Reversibility assessed after prolonged superfusion in drug-free solution.

    Main Results:

    • Transcainide reduced sodium current in a concentration-dependent manner (ED50 ≈ 0.5 μM).
    • Block exhibited minimal use-dependence and no significant accumulation during high-frequency stimulation.
    • Little to no recovery from block was observed even after hyperpolarization or 1-hour drug-free superfusion.
    • Block showed very little time or voltage dependence, distinguishing it from other antiarrhythmic agents.

    Conclusions:

    • Transcainide possesses unique electrophysiological properties characterized by potent, time- and voltage-independent sodium channel block.
    • These novel properties may offer a unique therapeutic spectrum for specific cardiac arrhythmias.
    • The drug's high potency and lack of rapid reversibility necessitate careful clinical use and monitoring.

    More Related Videos

    Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates07:42

    Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

    Published on: October 18, 2018

    Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice09:20

    Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

    Published on: July 5, 2021

    Related Concept Videos

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

    Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

    Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
    Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

    Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

    Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
    Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
    Antiepileptic Drugs: Sodium Channel Blockers01:08

    Antiepileptic Drugs: Sodium Channel Blockers

    Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
    Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
    Among the most commonly prescribed antiepileptic drugs are...
    Antiepileptic Drugs: Potassium Channel Activators01:20

    Antiepileptic Drugs: Potassium Channel Activators

    Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
    Ezogabine has gained approval as an adjunctive treatment...